Facebook
Twitter
LinkedIn
Forward
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|
This talk will review key features of obesity pathogenesis related to genetics, the brain, and energetics.
|
Insulin resistance (IR) is a common biochemical abnormality in patients with excess adiposity, obesity, and its complications.
|
Poor responders to common medical weight loss treatments is a challenging situation for clinicians.
|
Obesity is one of the leading causes of the development of type 2 diabetes mellitus.
|
Is the intersection of Childhood Obesity and pediatric sleep problems merely confined to a discussion of poor sleep habits leading to weight gain?
|
Obesity is one of the leading causes of preventable death. Obesity-related increases metabolic and cardiovascular risk occur at a lower body mass index in Asian adults.
|
In June of 2023 the AASLD updated the nomenclature for NAFLD to Metabolic dysfunction-Associated Steatotic Liver Disease(MASLD).
|
Obesity is a chronic, serious life threatening disease, but treatments exist. Obesity is associated with an increased risk of CVD and CV-associated mortality.
|
Join Dr.
|